ResearchMoz

Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth Description

GBI Research
Published Date » 2014-02-06
No. Of Pages » 101
   
 GBI Research has released its pharma report “Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth”. The systemic psoriasis market is forecast to grow substantially over the forecast period from $5.0 billion in 2013 to $10.4 billion in 2020, across the eight major markets. This growth will be driven by a rising treatment population and the continued uptake of biologics. Biologics will continue to drive market growth despite leading brands Enbrel (etanercept), Humira (adalimumab) and Remicade (infliximab) losing patent protection in most of the major markets over the forecast period. Although the market will suffer revenue losses as a result of sales erosion from biosimilar...
Table of Content

1 Table of Contents 1
1.1 List of Tables 4
1.2 List of Figures 5

2 Executive Summary 6
2.1 Changes to Treatment Usage Patterns will Drive Market Growth 6
2.2 Biologics to Gain Prominence as Promising Novel Drugs Enter the Market 6

3 Introduction 7
3.1 Overview 7
3.2 Epidemiology 8
3.3 Etiology, Co-morbidities and Risk Factors 9
3.3.1 Genetics 9
3.3.2 Psoriatic Arthritis 9
3.3.3 Mental Health Disorders 10
3.3.4 Metabolic Syndrome, Smoking, Diet and Alcohol Consumption 10
3.3.5 Infections 10
3.3.6 Köebner Phenomenon 11
3.3.7 Other Immune-mediated Diseases 11
3.4 Pathophysiology 11
3.5 Diagnosis 12
3.6 Treatment Options 12
3.6.1 Pharmacological Therapies 13
3.6.2 Non-pharmacological Therapies 14
3.6.3 Combination and Rotational Therapies 14
3.6.4 Quality of Life Assessments 15
3.7 Summary 15
3.8 GBI Research Report Guidance 15

4 Marketed Products 16
4.1 Overview 16
4.2 Methotrexate-based Products 16
4.3 Sandimmune/Neoral (cyclosporine/modified cyclosporine) – Novartis 17
4.4 Soriatane (acitretin) – Steifel Laboratories 18
4.5 Fumaderm (dimethyl fumarate and ethyl fumarate) – Biogen Idec 19
4.6 Humira (adalimumab) – Abbvie Inc. 20
4.7 Enbrel (etanercept) – Amgen Inc. 21
4.8 Remicade (infliximab) – Janssen Biotech 22
4.9 Stelara (ustekinumab) – Janssen Biotech 23
4.10 Marketed Products Heat Map 24

5 Pipeline 27
5.1 Overview 27
5.2 Pipeline Size and Distribution by Phase, Molecule Type and Program Type 28
5.3 Pipeline Distribution by Molecular Target 30
5.4 Clinical Trial Landscape 32
5.4.1 Clinical Trial Duration 32
5.4.2 Clinical Trial Size 36
5.5 Clinical trial failure rates 40
5.6 Primary and Secondary Endpoints 41
5.7 Summary of Psoriasis Clinical Trials 43
5.8 Promising pipeline molecules 43
5.8.1 Ixekizumab – Eli Lilly 43
5.8.2 Xeljanz (tofacitinib) – Pfizer 44
5.8.3 Brodalumab – Amgen 45
5.8.4 Apremilast – Celgene 46
5.8.5 Secukinumab – Alcon 47
5.9 Heat Map for Pipeline Products 47

6 Market Forecast to 2020 52
6.1 Overview 52
6.2 Global Market 52
6.3 North America 55
6.3.1 Treatment Usage Patterns 55
6.3.2 Annual Cost of Treatment 56
6.3.3 Market Size 58
6.4 Top Five EU Markets 59
6.4.1 Treatment Usage Patterns 59
6.4.2 Annual Cost of Treatment 60
6.4.3 Market Size 61
6.5 Japan 62
6.5.1 Treatment Usage Patterns 62
6.5.2 Annual Cost of Treatment 63
6.5.3 Market Size 64
6.6 Drivers and Barriers for the Systemic Psoriasis Therapeutics Market 65
6.6.1 Drivers 65
6.6.2 Barriers 65

7 Co-development and Licensing deals 67
7.1 Co-development Deals 67
7.1.1 Abbvie Enters into Co-development Agreement with Biotest for Tregalizumab 70
7.1.2 Lycera Enters into Research Agreement with Merck & Co. 70
7.1.3 LEO Pharma Enters into Research Agreement with 4SC Discovery for Inflammatory Skin Diseases 70
7.1.4 Amgen Enters into Co-Development Agreement with AstraZeneca for Five Human Monoclonal Antibodies Including Brodalumab 70
7.2 Licensing Deals 72
7.2.1 Leo Pharma Enters into Licensing Agreement with Virobay for Psoriasis Drug 75
7.2.2 Foamix Enters into Licensing Agreement with Dr. Reddy's Labs 75
7.2.3 Cipher Pharma Enters into Licensing Agreement with IBSA Institut Biochimique for Betesil Patch 75
7.2.4 Phenex Pharma Enters into Licensing Agreement with Janssen Biotech for Retinoid-Acid Receptor-Related Orphan Receptor Gamma t Program 75

8 Appendix 76
8.1 All Pipeline Drugs by Phase 76
8.1.1 Discovery 76
8.1.2 Preclinical 78
8.1.3 Phase I 82
8.1.4 Phase II 84
8.1.5 Phase III 86
8.1.6 Undisclosed 87
8.2 Market Forecasts to 2020 87
8.2.1 Major Developed Markets 87
8.2.2 US 88
8.2.3 UK 88
8.2.4 France 89
8.2.5 Germany 89
8.2.6 Italy 90
8.2.7 Spain 90
8.2.8 Japan 91
8.2.9 Canada 91
8.3 Abbreviations 92
8.4 References 93
8.5 References for Heat Maps 98
8.5.1 Marketed Products 98
8.5.2 Pipeline products 98
8.6 Methodology 100
8.6.1 Secondary Research 100
8.6.2 Therapeutic Landscape 100
8.7 Contact Us 100
8.8 Disclaimer 101

List of Tables


Table 1: Type of Psoriasis 8
Table 2: Systemic Psoriasis Therapeutics Market, Global, Pipeline, Discovery, 2014 76
Table 3: Systemic Psoriasis Therapeutics Market, Global, Pipeline, Preclinical/IND/CTA-filed, 2014 78
Table 4: Systemic Psoriasis Therapeutics Market, Global, Pipeline, Phase I, 2014 82
Table 5: Systemic Psoriasis Therapeutics Market, Global, Phase II, Discovery, 2014 84
Table 6: Systemic Psoriasis Therapeutics Market, Global, Pipeline, Phase III/Pre-registration, 2014 86
Table 7: Systemic Psoriasis Therapeutics Market, Global, Pipeline, Undisclosed, 2014 87
Table 8: Systemic Psoriasis Market Forecast, Global, 2013–2020 87
Table 9: Systemic Psoriasis Market Forecast, US, 2013–2020 88
Table 10: Systemic Psoriasis Market Forecast, UK, 2013–2020 88
Table 11: Systemic Psoriasis Market Forecast, France, 2013–2020 89
Table 12: Systemic Psoriasis Market Forecast, Germany, 2013–2020 89
Table 13: Systemic Psoriasis Market Forecast, Italy, 2013–2020 90
Table 14: Systemic Psoriasis Market Forecast, Spain, 2013–2020 90
Table 15: Systemic Psoriasis Market Forecast, Japan, 2013–2020 91
Table 16: Systemic Psoriasis Market Forecast, Canada, 2013–2020 91
Table 17: Breakdown of ‘Others’ Category 99
Table 18: Breakdown of ‘Combination’ Category 99

List of Figures


Figure 1: Systemic Psoriasis Therapeutics Market, Global, Market Size, 2013–2020 6
Figure 2: Psoriasis Treatment Algorithms 13
Figure 3: Heat Map for Marketed Products 24
Figure 4: Heat Map for Marketed Products (continued) 25
Figure 5: Psoriasis Therapeutics Market, Global, Pipeline, 2013 28
Figure 6: Psoriasis Therapeutics Market, Global, Pipeline by Molecular Target, 2013 30
Figure 7: Psoriasis Therapeutics Market, Global, Pipeline by Molecular Target, 2013 31
Figure 8: Psoriasis Therapeutics Market, Global, Pipeline, Clinical Trial Duration by Molecule Type, (months) 2006–2012 33
Figure 9: Psoriasis Therapeutics Market, Global, Pipeline, Clinical Trial Duration by Molecular Target, (months) 2006–2012 35
Figure 10: Psoriasis Therapeutics Market, Global, Pipeline, Clinical Trial Size by Molecule Type, (participants) 2006–2012 37
Figure 11: Psoriasis Therapeutics Market, Global, Pipeline, Clinical Trial Size by Molecular Target, (participants), 2006–2012 39
Figure 12: Psoriasis Therapeutics Market, Global, Clinical Trial Failure Rate, (%), 2006–2013 40
Figure 13: Psoriasis Therapeutics Market, Global, Frequency of Primary Endpoints Measured in Clinical Trials, (%), 2006–2012 41
Figure 14: Psoriasis Therapeutics Market, Global, Frequency of Secondary Endpoints Measured in Clinical Trials, (%), 2006–2012 42
Figure 15: Heat Map for Pipeline Products 48
Figure 16:Heat Map for Marketed Products 49
Figure 17:Heat Map for Marketed Products (continued) 50
Figure 18: Systemic Psoriasis Therapeutics Market, Global, Treatment Patterns (million), 2013–2020 52
Figure 19: Systemic Psoriasis Therapeutics Market, Global, Market Size ($bn), 2013–2020 54
Figure 20: Systemic Psoriasis Therapeutics Market, North America, Treatment Patterns, 2013–2020 55
Figure 21: Systemic Psoriasis Therapeutics Market, North America, Annual Cost of Treatment ($), 2013–2020 56
Figure 22: Systemic Psoriasis Therapeutics Market, North America, Market Size, 2013–2020 58
Figure 23: Systemic Psoriasis Therapeutics Market, Top Five EU Countries, Treatment Patterns (‘000), 2013–2020 59
Figure 24: Systemic Psoriasis Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment ($), 2013–2020 60
Figure 25: Systemic Psoriasis Therapeutics Market, Top Five EU Countries, Market Size ($m), 2013–2020 61
Figure 26: Systemic Psoriasis Therapeutics Market, Japan, Treatment Patterns (‘000), 2013–2020 62
Figure 27: Systemic Psoriasis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2013–2020 63
Figure 28: Systemic Psoriasis Therapeutics Market, Japan, Market Size ($m), 2013–2020 64
Figure 29: Psoriasis Therapeutics Market, Global, Co-development Deals, 2006–2013 67
Figure 30: Psoriasis Therapeutics Market, Global, Co-development Deals by Phase of Development, Molecule Type and Aggregate Deal Value ($m), 2006–2013 69
Figure 31: Psoriasis Therapeutics Market, Global, Licensing Deals, 2006–2013 72
Figure 32: Psoriasis Therapeutics Market, Licensing Deals by Phase, Molecule Type and Aggregate Deal Value ($m), 2006–2013 73

Upcoming Reports:

Passive Fire Protection Materials Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018
By - Transparency Market Research
The growth of accidents and the loss of assets caused due to fire on a global scale is one of the major factors driving the demand for passive fire protection materials. The global market for passive fire protection material is witnessing tremendous growth since the last decade. Some of the basic types of passive fire protection material used by the construction industry to prevent fire in buildings include fire doors, fire resisting cables, fire linings, fire resisting partitions, fire resisting glass, fire screens etc.  The global market for passive fire...
Epoxy Resins Market - Global Industry Size, Market Share, Trends, Analysis And Forecast, 2012 - 2018
By - Transparency Market Research
Epoxy resin is a malleable resin used for a number of applications. The most common application of these resins includes uses in laminates, insulators, jewelry, and others. Epoxy resins are popularly known for their electrical, mechanical, and heat resistant properties, due to which they are best suited in insulation applications. They are also available in a wide range of curing agent variants.  There is a growing market for epoxy resins in developed economies such as North America and Europe owing to their increasing use in coating processes, wind blades in wind mill...
Poland: canned vegetables market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the canned vegetables market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the canned vegetables market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Order cancellations not a sign of market slump: Airbus
Jul 31, 2014  
Leading aircraft manufacturer Airbus on Wednesday said that the recent wave of order cancellations for its commercial jetliners do not mean that the market has declined. The market is still strong and single-aisle jets deals are likely to return later. A total of 225 Airbus cancellations were reported since the beginning of this year. Of these, Dubai’s Emirates Airlines alone...
Leading Australian Universities Want to Hike Fees, Enroll Fewer Students
Jul 31, 2014  
Australia’s prestigious group of top eight universities, also known as the Group of Eight (Go8), has indicated plans of increasing tuition fees while reducing the number of students they enroll, a reform-backer has predicted. These decisions could be made if the universities are deregulated .  Arguing for this decision, the chairman of Go8, and vice chancellor of the ANU, Ian...
Bristol-Myers Squibb Posts USD 3.9 billion Revenues in 2014 Second Quarter
Jul 30, 2014  
Leading bio-pharmaceutical company Bristol-Myers Squibb has registered revenues of USD 3.9 billion in the 2014 second quarter. This marks a 4% decrease from the same period in 2013. The global revenues of the company (excluding the divested Diabetes Alliance), saw a 7% increase. In this quarter, the company’s results were underlined by steady global sales of nearly each of its...
Novartiss Simbrinza gets approval from the EU
Jul 30, 2014  
Glaucoma patients in Europe can easily obtain Novartis’ Simbrinza eye drops which are a combination of brimonidine tartrate and brinzolamide and it is without a beta-blocker. This eye drop has got the approval of the European Commission. Unlike the inefficient treatment provided by monotherapy, this eye drop aims at treating intraocular pressure or IOP in adults with ocular hypertension...
Second Treaty Between Zealand And Boehringer Ingelheim
Jul 30, 2014  
Denmark based Pharma group Zealand Pharma and Germany’s Boehringer Ingelheim have signed an accord to formulate new medicines for advanced and effective treatment of cardio-metabolic maladies. The collaboration between these two Pharma groups involves a new therapeutic peptide project from the list of preclinical programs of Zealand Pharma.  Both these companies are aiming...